Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Teva Branded Pharmaceutical Products R&D, Inc.
Age
4–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Written informed consent/assent
General good health
Asthma or COPD
Capable of understanding the requirements, risks, and benefits of study participation.
Able to demonstrate proper metered-dose inhaler use and technique.
You may not be if
History of life-threatening asthma or COPD that is defined for this protocol as an asthma or COPD episode that required intubation and/or was associated with hypercapnia, respiratory arrest or hypoxic seizures.
Culture-documented or suspected bacterial or viral infection of the upper or lower respiratory tract, sinus, or middle ear that is not resolved within 2 weeks of Screening Visit.
Is being treated with a long-acting β2-agonist alone.
Is currently being treated with Ventolin HFA.
Any asthma or COPD exacerbation requiring oral corticosteroids within 2 months of Screening Visit. A subject must not have had any hospitalization for asthma or COPD within 4 months prior to Screening Visit.
Historical or current evidence of a clinically significant non-asthmatic acute or chronic condition.
Uncontrolled hypertension
History of any adverse reaction to any component of the HFA-MDI formulation.
Participation in any investigational drug study within the 30 days preceding the Screening Visit.
Clareo Health | A Study to Evaluate the Integrated Dose Counter on an Albuterol Hydrofluoroalkane (HFA) Metered Dose Inhaler (MDI)
